FDA approves Monjuvi for relapsed, refractory follicular lymphoma
The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Category Added in a WPeMatico Campaign